Legal & General Group
AEGR

Legal & General Group’s Aegerion Pharmaceuticals AEGR Stock Holding History

Legal & General Group’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,289
Closed -$17K – 2951
2016
Q1 		$17K Hold
4,289
– – ﹤0.01% 2696
2015
Q4 		$44K Hold
4,289
– – ﹤0.01% 2524
2015
Q3 		$59K Hold
4,289
– – ﹤0.01% 2364
2015
Q2 		$79K Hold
4,289
– – ﹤0.01% 2297
2015
Q1 		$112K Hold
4,289
– – ﹤0.01% 1970
2014
Q4 		$92K Hold
4,289
– – ﹤0.01% 2039
2014
Q3 		$144K Buy
+4,289
New +$133K ﹤0.01% 1676

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Legal & General Group's AEGR Position: Q2 2016 in Review

Legal & General Group sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 4,289 shares — an estimated $17K sold.

Legal & General Group first reported a position in AEGR in Q3 2014 and held it in 7 quarters. The position peaked at $144K in Q3 2014. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • Legal & General Group reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Legal & General Group sold 4,289 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $17K.
  • Legal & General Group first reported a position in Aegerion Pharmaceuticals in Q3 2014 and held it in 7 quarters.
  • Legal & General Group's Aegerion Pharmaceuticals position peaked at $144K in Q3 2014.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Legal & General Group's 13F filing for Q2 2016, filed 16 Aug 2016.